Shots:
Sandoz commercializes Epruvy (Biosimilar, Lucentis) across Germany in PFS and vial forms, following an agreement with Formycon and Bioeq
Epruvy (ranibizumab)was approved by the EMA in Sep'24 to treat severe visual impairments like nAMD and other retinopathies and is marketed by Sandoz in Germany under a Bioeq license
Epruvy is available in vials and pre-filled syringes, offering a convenient treatment option in Germany
Ref: Formycon | Image: Formycon | Press Release
Related…
